Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester is a synthetic small molecule compound with the molecular formula C13H14N2O3S3 and a molecular weight of approximately 342.46 g/mol[3]. It contains a sulfamoyl group, a thiocarbamate moiety, and an ethyl thiophene ester linkage[1][2][4]. The compound is classified as experimental and has not been approved for any therapeutic use in the US or elsewhere[3]. Its primary known biological activity is arylesterase activity, with reported inhibition of carbonic anhydrase 2 (CA2), suggesting potential enzyme inhibitory properties[3]. There are no clinical trials or approved indications associated with this molecule as of the latest data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester.